Notable developments for the Watchman FLX LAAC device
Notable developments for the Watchman FLX LAAC Device: Data presented from two new sub-analyses of the SURPASS study out of the National Cardiovascular Data Registry (NCDR) LAAO Registry provided insights into real-world treatment strategies with the Watchman FLX LAAC Device
The first analysis assessed outcomes with different post-procedural antithrombotic therapies and demonstrated that patients treated with direct oral anticoagulants (DOAC) alone had the lowest risk of major adverse events in comparison to other drug regimens following the implant. The second analysis demonstrated that concomitant catheter ablation and LAAC with the Watchman FLX device was safe and had similar outcomes when compared to device implantation alone.
In addition, the latest preclinical data for the investigational Watchman FLX Pro LAAC Device demonstrated that its new thromboresistant coating may further reduce the risk of device-related thrombus and result in faster and more uniform tissue coverage on the device at 45 days post implant. The findings were also published in JACC Clinical Electrophysiology.
See- "Enhanced Thromboresistance and Endothelialization of a Novel Fluoropolymer-Coated Left Atrial Appendage Closure Device"; Walid I. Saliba MD , Kenji Kawai MD , Yu Sato MD , Edward Kopesky PhD MD, et al., .https://doi.org/10.1016/j.jacep.2023.04.013. JAAC.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins